Adolor Corporation (NasdaqGM: ADLR) announces Michael J. Fox Foundation funding for Parkinson's Research

FOR IMMEDIATE RELEASE
West Bloomfield, Michigan, United States of America (Free-Press-Release.com) June 11, 2011 -- Adolor Corporation (NasdaqGM: ADLR) is a bio-pharmaceutical company focused on the development and commercialization of novel prescription pain and pain-management products. Adolor's mission addresses a simple goal: to provide enhanced relief for the millions of people who suffer from pain each year.

Michael J. Fox Foundation for Parkinson's Research awarded Adolor funding to support their development of CAMORs for the treatment of LID associated with Parkinson's disease.

Adolor Corporation (NasdaqGM: ADLR) , currently trading at $1.50 per share, is undervalued according to Joe Capaldi at Professional Trading Systems Corporation (ProTSC). According to Capaldi, Adolor has five (5) unique drugs in it's pipeline. ENTEREG®, which is already approved for limited market for in-hospital use and is seeking wider approval, ADL5945, ADL7445, ADL6906 and Camors for Parkinson's disease.

When compared to Pharmasset, Inc. (Public, NASDAQ:VRUS) , currently trading at $119.00 per share with no drugs currently approved for market, Adolor Corporation (NasdaqGM: ADLR) is the next big drug company to significantly gap up. Valuations managers say Adolor is being quietly acquired by funds managers and other drug companies. Glaxo Smith Kline (Public, NYSE:GSK) , a leading health care company, has partnered with Adolor to bring ENTEREG® to market and has purchased a stake in the company.

Adolor Corporation (NasdaqGM: ADLR) , currently trading at $1.50 per share, Joe Capaldi projects $125.00 per share when one (1) of their next four (4) drugs reaches market.

Links:
http://www.adolor.com/research/index1.asp?page=r-d-pipeline

drug discovery     Joe Capaldi     Michael J. Fox Foundation     Parkinsons Disease     Potential Stock Gaps     stocks on the move     Undervalued Stock